Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Stemirna Therapeutics logo — company profile

Stemirna Therapeutics

Founded 2016 4 employees Series D Total: $1.33B Biotechnology, Pharmaceutical

General Information

Company Name Stemirna Therapeutics
Founded Year 2016
Employees 4
Industries Biotechnology, Pharmaceutical
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Stemirna Therapeutics. To contact Stemirna Therapeutics, visit stemirna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Stemirna Therapeutics compare?

A PDF of Stemirna Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Stemirna Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Stemirna Therapeutics

Stemirna Therapeutics is a biotechnology and pharmaceutical startup founded in 2016. The company specializes in RNA technology for drug development, with a focus on leveraging the full potential of RNA science. Stemirna Therapeutics boasts a portfolio of over a dozen independently-developed mRNA drug projects, targeting areas such as mRNA-based personalized cancer vaccines, mRNA vaccines for infectious diseases, treatments for protein defect diseases, and genetic disorders. Their primary mission is to offer solutions for cancer and infectious diseases, ultimately aiming to enhance patient care. The most recent funding milestone for Stemirna Therapeutics was a Series D investment on 25 May 2023. The participating investors for this round are not specified. This funding can be assumed to support the company's ongoing research and development efforts, as well as to further advance its mRNA drug projects. Stemirna Therapeutics stands at the forefront of groundbreaking RNA technology within the biotech and pharmaceutical industries. With its clear focus on addressing critical medical needs such as cancer and infectious diseases, the company presents an intriguing investment opportunity within the rapidly evolving landscape of healthcare and life sciences.

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series D Undisclosed -
25 May 2023
Series C CNY1.20B 10
OrbiMed Oceanpine Capital Tsing Capital
OrbiMed, Oceanpine Capital +8
03 Jun 2021
Series B Undisclosed 1
LC Ventures
LC Ventures
01 Sep 2020
Series A CNY30.00M 2
LC Ventures
LC Ventures, Shanghai Junshi Biosciences
01 Feb 2020
Series A CNY100.00M 4
Lapam Capital Zhangjiang Torch Venture Capital Co
Lapam Capital, Zhangjiang Torch Venture Capital Co +2
12 Aug 2019
Seed Round Undisclosed 1
Longpan Investment
01 Jun 2018
Angel Round Undisclosed -
01 Apr 2017

Stemirna Therapeutics Alternatives & Competitors

View All Alternatives
Stemirna Therapeutics vs
Santaris Pharma
Santaris Pharma

Pioneering RNA-targeted therapies with rapid LNA-based drug development for diverse disease states.

Venture round
Biotechnology, Health Care
Stemirna Therapeutics vs
ADARx Pharmaceuticals Inc.
ADARx Pharmaceuticals Inc. United States

Our vision is to provide effective and safe RNA therapeutics to patients who suffer from intractable...

Series C
94 employees
Biotechnology, Health Care
Stemirna Therapeutics vs
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. United States

Clinical-stage biotech company transforming how disease is treated through targeted protein degradat...

IPO
111 employees
Biotechnology, Health Care
View all alternatives

FAQ About Stemirna Therapeutics

Stemirna Therapeutics is a company centered on RNA technology for drug development, aiming to harness the full potential of RNA science. With a portfolio of more than a dozen independently-developed mRNA drug projects, the company focuses on mRNA-based personalized cancer vaccines, mRNA vaccines for...
Stemirna Therapeutics was founded in 2016.
Stemirna Therapeutics operates in Biotechnology and Pharmaceutical.
Stemirna Therapeutics has approximately 4 employees.
Stemirna Therapeutics has completed 7 funding rounds, raising a total of $1.33B. The latest funding stage is Series D.
Top alternatives and competitors to Stemirna Therapeutics include Santaris Pharma, ADARx Pharmaceuticals Inc., C4 Therapeutics, Inc., Gain Therapeutics, GPCR Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stemirna Therapeutics and Santaris Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Stemirna Therapeutics, https://bouncewatch.com/company/stemirna-therapeutics, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout